Artivion Q1 revenue $83.2M (+8% GAAP, +10% constant currency); raises FY guidance

ARTIVION, INC.

2023-Q1 EPS reported -$0.33 revenue$83,229,000

Net loss ($13.5M) or ($0.33)/share; non-GAAP net income $769k ($0.02)/share.
On-X revenue up 24% constant currency; aortic stent grafts up 8% constant currency.
FY 2023 revenue guidance raised to $337-348M (prev. $331-343M); constant currency growth now 9-12%.
Adjusted EBITDA guidance increased to >$52M (prev. >$50M); EBITDA growth >25% YoY expected.
FDA issued Approvable Letter for PerClot PMA; $14.3M milestone payment expected after final approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARTIVION, INC. updated its full year 2023 guidance (raised).

Period: full year 2023
Guidance: raised
Result: guidance update

Exact text from the filing

Artivion is raising its revenue guidance range and now expects constant currency revenue growth of between 9% and 12%, compared to the previous range of between 8% and 12%, for the full year 2023 compared to 2022. The Company expects revenues to be in a range of between $337.0 million and $348.0 million, compared to the previous range of between $331.0 million and $343.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARTIVION, INC. reported first quarter ended March 31, 2023 results: revenue $83.2 million, net income ($13.5) million, EPS ($0.33) per fully diluted common share.

Period: first quarter ended March 31, 2023
Revenue: $83.2 million
Net income: ($13.5) million
EPS: ($0.33) per fully diluted common share
Result: reported results

Exact text from the filing

Total revenues for the first quarter of 2023 were $83.2 million, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis, both compared to the first quarter of 2022. Net loss for the first quarter of 2023 was ($13.5) million, or ($0.33) per fully diluted common share, compared to net loss of ($3.4) million, or ($0.08) per fully diluted common share for the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

ARTIVION, INC. filing history →

Source: SEC EDGAR

accession 0000784199-23-000084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.